• 핵의학기술
• /
• 제13권3호
• /
• pp.137-142
• /
• 2009

목적: WHO (world health organization)에서는 골밀도뿐만 아니라 대규모 역학연구에서 정리된 골절의 위험인자 분석을 통하여 10년 내 골절위험도(10-year fracture probability)를 실제적으로 임상에 적용시킬 수 있는 소프트웨어 프로그램인 FRAX Tool (fracture risk assessment)이 2008년에 공개되었다. 본 연구는 기존에 사용하고 있는 GE Prodigy사의 골절위험도평가와 $FRAX^{TM}$를 이용한 골절위험도평가를 비교분석하고자 한다. 검사방법: 본원에 골밀도 검사를 시행한 201명($55{\pm}3.5$세)의 여자를 대상으로 GE Prodigy를 이용하여 Femur를 측정하였다. 측정한 Femoral Neck의 BMD (bone mineral density)를 구하여 GE Prodigy의 T-값과 골절위험인자를 고려하지 않은 $FRAX^{TM}$의 T-값를 사용하여 10년 내 대퇴골 골절위험도와 주요한 골다공증성 골절 위험도를 계산하여 SPSS통계프로그램으로 GE Prodigy의 골절위험도 평가와 $FRAX^{TM}$의 골절위험도 평가를 비교분석하였다. 결과: GE Prodigy의 T-값($-0.52{\pm}0.97$)과 $FRAX^{TM}$의 T-값 ($-1.45{\pm}0.81$)은 통계적으로 유의한 차이가 있었으며(p=0.000), GE Prodigy의 주요한 골다공증성 골절위험도($9.15{\pm}3.71$)와 $FRAX^{TM}$의 주요한 골다공증성 골절위험도($4.87{\pm}1.51$)도 또한 통계적으로 유의한 차이가 있었다(p=0.000). 그리고 GE Prodigy의 10년내 대퇴골 골절위험도($1.56{\pm}1.48$)와 $FRAX^{TM}$의 10년 내 대퇴골골절위험도($0.53{\pm}0.61$)도 통계적으로 유의한 차이를 보였다(p=0.000). 결론: GE Prodigy와 $FRAX^{TM}$에서 측정한 골절의 절대위험도는 통계적으로 유의한 차이를 보였다. 특히 GE Prodigy의 T-값, 주요한 골다공증성 골절위험도, 10년 내 대퇴골 골절위험도가 높게 측정되었다. 향후 $FRAX^{TM}$에 대한 평가 및 적용에 관한 연구가 필요할 것으로 생각된다.

• Journal of Korean Neurosurgical Society
• /
• 제58권4호
• /
• pp.346-349
• /
• 2015

Objective : To investigate the value of lumbar bone mineral density (BMD) in fracture risk assessment (FRAX) tool. Methods : One hundred and ten patients aged over 60 years were enrolled and divided into 2 groups as non-osteoporotic vertebral fracture (OVF) and OVF groups. The 10-year-risk of major osteoporotic vertebral fracture of each group was calculated by FRAX tool with femoral and lumbar spine BMDs to compare the usefulness of lumbar spine BMD in prediction of OVF. The blood level of osteocalcin and C-terminal telopeptide (CTX) as markers of activities of osteoblast and osteoclast, respectively were analyzed using the institutional database. Results : In the OVF group, the ratio of patients with previous fracture history or use of glucocorticoid was higher than those in non-OVF group (p=0.000 and 0.030, respectively). The levels of T-score of femur neck and lumbar spine in OVF group were significantly lower than those in non-OVF group (p=0.001 and 0.000, respectively). The risk of OVF in FRAX using femur BMD in non-OVF and OVF groups was $6.7{\pm}6.13$ and $11.4{\pm}10.06$, respectively (p=0.007). The risk of using lumbar BMD in the 2 groups was $6.9{\pm}8.91$ and $15.1{\pm}15.08$, respectively (p=0.002). The areas under the receiver operator characteristic curve in the FRAX risk with lumbar and femur neck BMD were 0.726 and 0.684, respectively. The comparison of osteocalcin and CTX was not significant (p=0.162 and 0.369, respectively). Conclusion : In our study, the 10-year risk of major osteoporotic fracture in the OVF group of our study was lower than the recommended threshold of intervention for osteoporosis. Hence, a lower threshold for the treatment of osteoporosis may be set for the Korean population to prevent OVF. In the prediction of symptomatic OVF, FRAX tool using lumbar spine BMD may be more useful than that using femur neck BMD.

• 핵의학기술
• /
• 제13권3호
• /
• pp.132-136
• /
• 2009

목적: WHO(world health organization)에서 10년 내 골절 위험도라는 새로운 개념의 FRAX (fracture risk assessment) Tool을 2008년 초에 발표하였다. FRAX에서는 기존의 골절위험도와는 달리 여러 가지 위험인자가 고려되었다. 본 연구에서는 골절 위험인자 변화에 따른 골절 위험도를 알아보고자 한다. 대상 및 방법: 부산대학교 병원에서 50~60세의 여성 수검자 50명을 대상으로, GE사의 Lunar-prodigy로 골밀도를 측정하였다. 개인의 연령, 체중, 키를 바탕으로 대퇴경부의 T-score를 산출하였다. 골절 위험인자를 고려하지 않은 T-Score에서의 골절위험도를 대조군으로 하였다. 골절의 경험유무, 골절의 가족력(부모에 한함), 현재의 흡연 여부, 당질코르티코이드의 사용유무, 류마티스 관절염의 유무, 이차성 골다공증의 유무, 알콜의 평균섭취량의 7가지 항목을 실험군으로 하여 각각의 항목을 하나가 '유'이면 나머지는 모두 '무'로 하여 골절위험도를 비교하였으며, 골절위험도는 신체 주요부위 골절과 대퇴경부의 골절로 나누어 결과를 산출하였다. 통계는 SPSS 12.0의 t-test를 사용하였다. 결과: 대조군과 실험군 간의 골절위험도의 평균증가율은 먼저 신체 주요부위와 실험군을 알아보면 골절의 경험 -74% 증가, 골절의 가족력 -96% 증가, 흡연 -2% 증가, 당질코르티코이드 사용 -61% 증가, 류마티스 관절염 -29% 증가, 이차성 골다공증 -0.18% 감소, 알콜의 섭취 -20% 증가하였다. 대퇴골 경부와 실험군은 골절의 경험-84% 증가, 골절의 가족력 -5% 증가, 흡연 -72% 증가, 당질코르티코이드의 사용-84% 증가, 류마티스관절염 -40% 증가, 이차성 골다공증 -1.69% 감소, 알콜의 섭취 -52%가 증가하였다. 결론: 신체 주요부위와 대퇴골 경부에서 위험인자 항목마다 골절위험도의 각기 다른 증가율을 보였으나 이차성 골다공증의 경우에는 유의확률이 낮아 연관성이 다소 떨어짐을 확인하였다. 이와 더불어 각각의 인자가 신체 주요부위에서의 골절위험도를 높이는 비중과 대퇴골경부에서의 골절위험도를 높이는 비중에서 기여도가 다름을 알 수 있었다.

• Asian Spine Journal
• /
• 제12권6호
• /
• pp.992-997
• /
• 2018

Study Design: Feasibility study. Purpose: To evaluate the feasibility of using serum pentosidine level as a potential marker for osteoporotic vertebral compression fracture (OVCF). Overview of Literature: A review of previous studies suggests a negative correlation between serum pentosidine concentration and bone strength. However, it is unclear whether serum pentosidine level might be a potential marker of OVCF in Koreans. Methods: Forty patients who underwent bone mineral density examination were included in this study, and their serum pentosidine levels were prospectively analyzed. Serum pentosidine level was evaluated using enzyme-linked immunosorbent assay. Among all the patients, 11 with OVCF were assigned to the vertebral fracture group and 29 who did not have vertebral fracture were included in the non-fracture group. In addition, we used the Fracture Risk Assessment (FRAX) tool Korean version for assessing the 10-year probability of fracture. Results: There was a statistically significant difference in the mean serum pentosidine level (p=0.04) of the vertebral fracture group (110.8 ng/mL) and the non-fracture group (64.3 ng/mL). Logistic regression analyses showed that serum pentosidine was significantly associated with OVCF. The vertebral fracture group had significantly higher 10-year probability of major osteoporotic fracture as per FRAX than the non-fracture group. There was a positive correlation between pentosidine level and FRAX results (r=0.35, p=0.02). Conclusions: These results suggest that increased serum pentosidine level could be a potential marker for OVCF.

• 한국임상약학회지
• /
• 제30권3호
• /
• pp.196-205
• /
• 2020

Background: The indication of denosumab for osteoporosis was expanded from second-line to first-line therapy in 2019. The aim of this study was to evaluate the efficacy of denosumab as both first- and second-line therapy in postmenopausal women with osteoporosis and osteopenia with risk factors by using the Fracture Risk Assessment Tool (FRAX). Methods: We conducted a medication use evaluation of denosumab in 98 patients who had been treated three or more times for osteoporosis or osteopenia at Chungnam National University Hospital from July 1^st, 2017 to January 31^st, 2020. Risk factors were identified using quantitative N-gram analyses of FRAX estimations. Patient information, including menopause status and results of bone mineral density tests (T-score), was obtained from electronic medical records. Results: Age, body mass index (BMI), prior medication use, and T-score were identified as risk factors and were included as variables in the evaluation of denosumab use. Since no significant differences were detected between groups, denosumab is likely effective regardless of age or BMI. In addition, no significant difference was detected in T-scores following denosumab treatment, between groups who took bisphosphonates and selective estrogen receptor modulators (SERMs) with denosumab as first-line therapy for postmenopausal osteoporosis. Denosumab may, therefore, be effective as second-line therapy. Conclusion: Efficacy of denosumab was evaluated in postmenopausal women with osteoporosis. Denosumab may be used as first- and second-line therapy regardless of age, BMI, and prior use of bisphosphonates and SERMs.

• 대한골대사학회지
• /
• 제25권4호
• /
• pp.195-211
• /
• 2018

Background: To develop guidelines and recommendations to prevent and treat glucocorticoid (GC)-induced osteoporosis (GIOP) in Korea. Methods: The Korean Society for Bone and Mineral Research and the Korean College of Rheumatology have developed this guideline based on Guidance for the Development of Clinical Practice Guidelines ver. 1.0 established by the National Evidence-Based Healthcare Collaborating Agency. This guideline was developed by adapting previously published guidelines, and a systematic review and quality assessment were performed. Results: This guideline applies to adults aged ${\geq}19years$ who are using or plan to use GCs. It does not include children and adolescents. An initial assessment of fracture risk should be performed within 6 months of initial GC use. Fracture risk should be estimated using the fracture-risk assessment tool (FRAX) after adjustments for GC dose, history of osteoporotic fractures, and bone mineral density (BMD) results. All patients administered with prednisolone or an equivalent medication at a dose ${\geq}2.5mg/day$ for ${\geq}3months$ are recommended to use adequate calcium and vitamin D during treatment. Patients showing a moderate-to-high fracture risk should be treated with additional medication for osteoporosis. All patients continuing GC therapy should undergo annual BMD testing, vertebral X-ray, and fracture risk assessment using FRAX. When treatment failure is suspected, switching to another drug should be considered. Conclusions: This guideline is intended to guide clinicians in the prevention and treatment of GIOP.

• 터널과지하공간
• /
• 제33권1호
• /
• pp.57-69
• /
• 2023

본 연구에서는 2차원 수리-역학적연계 개별요소모델링(DEM)을 사용하여 네델란드 그로닝엔(Groningen) 천연가스전 저류층의 유발지진을 모사하였다. 수치해석 코드는 ITASCA社의 상용프로그램인 PFC2D (Particle Flow Code 2D)를 사용하였으며 본 수치해석 연구에 적용하기 위해 수리-역학적 연계 모델 외 1) 비균질 저류층 압력분포 초기화, 2) 비선형 압력-시간이력 경계조건, 3) 국소 응력 분포 계산 등의 개별모듈을 추가개발, 적용하였다. 그로닝엔 가스전에 분포하는 복잡한 단층 형상을 포함하는 40 × 50 km² 크기의 2차원 모델을 생성하였고, 1960년부터 2020년까지 약 60년 동안의 가스생산, 즉 압 력저하로 인한 단층의 파괴거동을 모사하였다. 유발지진의 시공간적 발생을 수치해석모델로 재현하였고 그 발생 메커니즘을 규명하였다. 또한 저류층 압축으로부터 지표에서의 지반침하의 분포를 예측하였고 그로닝엔에서의 실측자료 사이에 유사성을 확인할 수 있었다. 이를 통해 본 연구에서 소개한 2차원 수리-역학적연계 개별요소모델링(DEM)의 복잡한 지질조건과 수리-역학적 연계 프로세스에 의한 단층거동을 구현할 수 있는 툴(tool)로서의 활용성을 확인하였다.

• 대한한의학회지
• /
• 제42권2호
• /
• pp.90-97
• /
• 2021

DXA로 측정한 요추 부위와 대퇴골경의 골밀도 수치가 2년간 지속적으로 연령대 평균 이하였던 중년의 사무직 남성 환자가 접골탕을 복용하고 골밀도 수치가 개선되었다.

• 한국임상약학회지
• /
• 제30권1호
• /
• pp.51-58
• /
• 2020

Background: Prevention of osteoporosis and bone fracture is one of the important issues for liver transplant recipients because a long history of liver disease and lifelong use of immunosuppressants, including corticosteroids, may cause these diseases. In this study, we aimed to analyze liver recipient bone status, 10-year fracture risk, and medication history. Methods: The electronic medical records of adult patients aged >40 years who received liver transplantation at Seoul National University Bundang Hospital between January 2009 and June 2017 were reviewed retrospectively. On the basis of their bone mineral density and fracture history, their fracture risks were analyzed using the Korean fracture risk assessment tool. Results: A total of 57 liver transplant recipients were treated with corticosteroids during a mean of 8.8 months after transplantation. 30 patients (52.6%) showed bone metabolism dysfunction such as osteopenia or osteoporosis. The 10-year femoral fracture risk was 2.1%, and dual-energy X-ray absorptiometry monitoring was performed, including right before liver transplantation every 27.5±19.2 months. The mean femoral bone mineral density decreased by -7.2%±7.3%. Four patients (7.0%) had a fracture after liver transplantation. Osteoporotic fracture occurred in 3 patients with osteoporosis (25.0%). Among the osteopenia patients with moderate fracture risk who were not treated with bisphosphonate, 1 patient (12.5%) had a history of bone fracture after liver transplantation. Conclusions: Considering the deterioration of bone density and moderate fracture risk, medication for osteoporosis should be prescribed to liver transplant recipients with regular monitoring of bone density after transplantation.